- Home
- OABI vs DBI Comparison
OABI vs DBI Comparison
Compare OABI & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- DBI
- Stock Information
- Founded
- OABI 2012
- DBI 1991
- Country
- OABI United States
- DBI United States
- Employees
- OABI N/A
- DBI N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- OABI Health Care
- DBI Consumer Discretionary
- Exchange
- OABI Nasdaq
- DBI Nasdaq
- Market Cap
- OABI 185.9M
- DBI 178.0M
- IPO Year
- OABI N/A
- DBI 1991
- Fundamental
- Price
- OABI $1.38
- DBI $3.64
- Analyst Decision
- OABI Strong Buy
- DBI Hold
- Analyst Count
- OABI 3
- DBI 2
- Target Price
- OABI $7.00
- DBI $4.75
- AVG Volume (30 Days)
- OABI 953.8K
- DBI 1.1M
- Earning Date
- OABI 05-08-2025
- DBI 06-10-2025
- Dividend Yield
- OABI N/A
- DBI 5.48%
- EPS Growth
- OABI N/A
- DBI N/A
- EPS
- OABI N/A
- DBI N/A
- Revenue
- OABI $26,744,000.00
- DBI $3,009,262,000.00
- Revenue This Year
- OABI N/A
- DBI $2.22
- Revenue Next Year
- OABI $40.06
- DBI $2.18
- P/E Ratio
- OABI N/A
- DBI N/A
- Revenue Growth
- OABI 27.07
- DBI N/A
- 52 Week Low
- OABI $1.22
- DBI $2.44
- 52 Week High
- OABI $4.96
- DBI $8.75
- Technical
- Relative Strength Index (RSI)
- OABI 39.15
- DBI 56.70
- Support Level
- OABI $1.22
- DBI $3.32
- Resistance Level
- OABI $1.42
- DBI $3.76
- Average True Range (ATR)
- OABI 0.08
- DBI 0.23
- MACD
- OABI 0.03
- DBI 0.01
- Stochastic Oscillator
- OABI 39.02
- DBI 74.31
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.